- Home
- NBIX vs DOCU Comparison
NBIX vs DOCU Comparison
Compare NBIX & DOCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- DOCU
- Stock Information
- Founded
- NBIX 1992
- DOCU 2003
- Country
- NBIX United States
- DOCU United States
- Employees
- NBIX N/A
- DOCU N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- DOCU EDP Services
- Sector
- NBIX Health Care
- DOCU Technology
- Exchange
- NBIX Nasdaq
- DOCU Nasdaq
- Market Cap
- NBIX 13.2B
- DOCU 14.5B
- IPO Year
- NBIX 1996
- DOCU 2018
- Fundamental
- Price
- NBIX $139.60
- DOCU $76.66
- Analyst Decision
- NBIX Strong Buy
- DOCU Hold
- Analyst Count
- NBIX 18
- DOCU 15
- Target Price
- NBIX $160.94
- DOCU $91.42
- AVG Volume (30 Days)
- NBIX 782.5K
- DOCU 2.3M
- Earning Date
- NBIX 10-29-2025
- DOCU 09-04-2025
- Dividend Yield
- NBIX N/A
- DOCU N/A
- EPS Growth
- NBIX 2.97
- DOCU 922.41
- EPS
- NBIX 3.39
- DOCU 5.25
- Revenue
- NBIX $2,509,900,000.00
- DOCU $3,030,753,000.00
- Revenue This Year
- NBIX $20.66
- DOCU $8.31
- Revenue Next Year
- NBIX $14.64
- DOCU $6.61
- P/E Ratio
- NBIX $40.91
- DOCU $14.61
- Revenue Growth
- NBIX 18.42
- DOCU 7.85
- 52 Week Low
- NBIX $84.23
- DOCU $54.32
- 52 Week High
- NBIX $154.61
- DOCU $107.86
- Technical
- Relative Strength Index (RSI)
- NBIX 68.09
- DOCU 57.07
- Support Level
- NBIX $133.62
- DOCU $72.44
- Resistance Level
- NBIX $137.03
- DOCU $75.21
- Average True Range (ATR)
- NBIX 2.36
- DOCU 2.04
- MACD
- NBIX 0.83
- DOCU 0.85
- Stochastic Oscillator
- NBIX 97.44
- DOCU 95.11
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.